Compare RMT & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RMT | PRTC |
|---|---|---|
| Founded | 1993 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 460.2M | 386.7M |
| IPO Year | N/A | N/A |
| Metric | RMT | PRTC |
|---|---|---|
| Price | $10.48 | $16.64 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 111.5K | 2.0K |
| Earning Date | 01-01-0001 | 08-28-2025 |
| Dividend Yield | ★ 7.37% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.49 | 0.20 |
| Revenue | N/A | ★ $6,391,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $6.18 | $8.02 |
| Revenue Growth | N/A | ★ 1265.60 |
| 52 Week Low | $7.67 | $13.30 |
| 52 Week High | $9.51 | $20.00 |
| Indicator | RMT | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | 50.19 | 48.09 |
| Support Level | $10.43 | $16.72 |
| Resistance Level | $10.69 | $16.99 |
| Average True Range (ATR) | 0.15 | 0.40 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 33.19 | 30.88 |
Royce Micro-Cap Trust Inc is a diversified closed-end investment company. The company is engaged in investing in micro-cap securities. It invests in the consumer discretionary sector including auto components, automobiles, diversified consumer services, hotels, restaurants and leisure, household durables, internet and catalog retail, leisure products, media, multiline retail, textiles, apparels, and luxury goods, Consumer staples sector including beverages, food, and staples retailing, food products, and personal products, Energy sector including energy equipment and services, and oil, gas, and consumable fuels. The company also invests in other sectors including healthcare, financials, industrials, IT, telecommunications, and materials.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.